BMY Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2022-03-24 | 2020 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,687,115 | 0 | 13,457,248 | 4,201,602 | 804,937 | 20,150,902 |
| 2022-03-24 | 2020 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,687,115 | 0 | 13,457,248 | 4,201,602 | 804,937 | 20,150,902 |
| 2022-03-24 | 2019 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,650,000 | 0 | 12,545,754 | 3,885,540 | 685,959 | 18,767,253 |
| 2022-03-24 | 2019 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,650,000 | 0 | 12,545,754 | 3,885,540 | 685,959 | 18,767,253 |
| 2022-03-24 | 2019 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,650,000 | 0 | 12,545,754 | 3,885,540 | 685,959 | 18,767,253 |
| 2022-03-24 | 2021 | David V. Elkins EVP and Chief Financial Officer | 1,027,005 | 525,000 | 4,716,137 | 1,342,169 | 284,749 | 7,895,060 |
| 2022-03-24 | 2021 | David V. Elkins EVP and Chief Financial Officer | 1,027,005 | 525,000 | 4,716,137 | 1,342,169 | 284,749 | 7,895,060 |
| 2022-03-24 | 2021 | David V. Elkins EVP and Chief Financial Officer | 1,027,005 | 525,000 | 4,716,137 | 1,342,169 | 284,749 | 7,895,060 |
| 2022-03-24 | 2020 | David V. Elkins EVP and Chief Financial Officer | 1,015,075 | 525,000 | 4,409,796 | 1,684,892 | 17,100 | 7,651,863 |
| 2022-03-24 | 2020 | David V. Elkins EVP and Chief Financial Officer | 1,015,075 | 525,000 | 4,409,796 | 1,684,892 | 17,100 | 7,651,863 |
| 2022-03-24 | 2020 | David V. Elkins EVP and Chief Financial Officer | 1,015,075 | 525,000 | 4,409,796 | 1,684,892 | 17,100 | 7,651,863 |
| 2022-03-24 | 2019 | David V. Elkins EVP and Chief Financial Officer | 116,667 | 1,050,000 | 1,865,662 | 1,323,722 | 15,500 | 4,371,551 |
| 2022-03-24 | 2019 | David V. Elkins EVP and Chief Financial Officer | 116,667 | 1,050,000 | 1,865,662 | 1,323,722 | 15,500 | 4,371,551 |
| 2022-03-24 | 2019 | David V. Elkins EVP and Chief Financial Officer | 116,667 | 1,050,000 | 1,865,662 | 1,323,722 | 15,500 | 4,371,551 |
| 2022-03-24 | 2021 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,036,972 | 500,000 | 4,588,306 | 1,355,194 | 321,639 | 7,802,111 |
| 2022-03-24 | 2021 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,036,972 | 500,000 | 4,588,306 | 1,355,194 | 321,639 | 7,802,111 |
| 2022-03-24 | 2021 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,036,972 | 500,000 | 4,588,306 | 1,355,194 | 321,639 | 7,802,111 |
| 2022-03-24 | 2020 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,022,500 | 500,000 | 4,079,065 | 1,697,239 | 17,100 | 7,315,904 |
| 2022-03-24 | 2020 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,022,500 | 500,000 | 4,079,065 | 1,697,239 | 17,100 | 7,315,904 |
| 2022-03-24 | 2020 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 1,022,500 | 500,000 | 4,079,065 | 1,697,239 | 17,100 | 7,315,904 |
| 2022-03-24 | 2019 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 891,259 | 0 | 3,250,793 | 1,399,997 | 199,601 | 5,741,650 |
| 2022-03-24 | 2019 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 891,259 | 0 | 3,250,793 | 1,399,997 | 199,601 | 5,741,650 |
| 2022-03-24 | 2019 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 891,259 | 0 | 3,250,793 | 1,399,997 | 199,601 | 5,741,650 |
| 2022-03-24 | 2020 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 952,603 | 0 | 3,210,894 | 1,581,713 | 247,023 | 5,992,233 |
| 2022-03-24 | 2021 | Sandra Leung EVP and General Counsel | 1,100,196 | 0 | 3,434,134 | 1,298,162 | 329,092 | 6,161,584 |
| 2022-03-24 | 2021 | Sandra Leung EVP and General Counsel | 1,100,196 | 0 | 3,434,134 | 1,298,162 | 329,092 | 6,161,584 |
| 2022-03-24 | 2021 | Sandra Leung EVP and General Counsel | 1,100,196 | 0 | 3,434,134 | 1,298,162 | 329,092 | 6,161,584 |
| 2022-03-24 | 2019 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 116,667 | 1,000,000 | 1,865,662 | 1,241,604 | 11,550 | 4,235,483 |
| 2022-03-24 | 2019 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 116,667 | 1,000,000 | 1,865,662 | 1,241,604 | 11,550 | 4,235,483 |
| 2022-03-24 | 2019 | Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. EVP, Research and Early Development | 116,667 | 1,000,000 | 1,865,662 | 1,241,604 | 11,550 | 4,235,483 |
| 2022-03-24 | 2021 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 1,020,118 | 0 | 4,095,864 | 1,313,855 | 273,192 | 6,703,029 |
| 2022-03-24 | 2021 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 1,020,118 | 0 | 4,095,864 | 1,313,855 | 273,192 | 6,703,029 |
| 2022-03-24 | 2021 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 1,020,118 | 0 | 4,095,864 | 1,313,855 | 273,192 | 6,703,029 |
| 2022-03-24 | 2020 | Sandra Leung EVP and General Counsel | 1,068,271 | 0 | 3,330,729 | 1,642,236 | 318,570 | 7,243,945 |
| 2022-03-24 | 2020 | Sandra Leung EVP and General Counsel | 1,068,271 | 0 | 3,330,729 | 1,642,236 | 318,570 | 7,243,945 |
| 2022-03-24 | 2020 | Sandra Leung EVP and General Counsel | 1,068,271 | 0 | 3,330,729 | 1,642,236 | 318,570 | 7,243,945 |
| 2022-03-24 | 2019 | Sandra Leung EVP and General Counsel | 1,008,635 | 0 | 3,172,998 | 1,586,482 | 322,655 | 7,516,457 |
| 2022-03-24 | 2019 | Sandra Leung EVP and General Counsel | 1,008,635 | 0 | 3,172,998 | 1,586,482 | 322,655 | 7,516,457 |
| 2022-03-24 | 2019 | Sandra Leung EVP and General Counsel | 1,008,635 | 0 | 3,172,998 | 1,586,482 | 322,655 | 7,516,457 |
| 2022-03-24 | 2020 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 952,603 | 0 | 3,210,894 | 1,581,713 | 247,023 | 5,992,233 |
| 2022-03-24 | 2020 | Christopher Boerner, Ph.D. EVP and Chief Commercialization Officer | 952,603 | 0 | 3,210,894 | 1,581,713 | 247,023 | 5,992,233 |
| 2022-03-24 | 2021 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,700,000 | 0 | 13,965,989 | 3,410,625 | 708,192 | 19,784,806 |
| 2022-03-24 | 2021 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,700,000 | 0 | 13,965,989 | 3,410,625 | 708,192 | 19,784,806 |
| 2022-03-24 | 2021 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,700,000 | 0 | 13,965,989 | 3,410,625 | 708,192 | 19,784,806 |
| 2022-03-24 | 2020 | Giovanni Caforio, M.D. Board Chair and Chief Executive Officer | 1,687,115 | 0 | 13,457,248 | 4,201,602 | 804,937 | 20,150,902 |
| 2019-04-30 | 2017 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 796,154 | 1,400,000 | 4,425,587 | 1,576,706 | 113,522 | 8,311,969 |
| 2019-04-30 | 2018 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,637,500 | 0 | 13,011,542 | 4,066,322 | 664,391 | 19,379,755 |
| 2019-04-30 | 2018 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,637,500 | 0 | 13,011,542 | 4,066,322 | 664,391 | 19,379,755 |
| 2019-04-30 | 2018 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,637,500 | 0 | 13,011,542 | 4,066,322 | 664,391 | 19,379,755 |
| 2019-04-30 | 2017 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,587,500 | 0 | 12,650,528 | 3,899,094 | 550,001 | 18,687,123 |
| 2019-04-30 | 2017 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,587,500 | 0 | 12,650,528 | 3,899,094 | 550,001 | 18,687,123 |
| 2019-04-30 | 2017 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,587,500 | 0 | 12,650,528 | 3,899,094 | 550,001 | 18,687,123 |
| 2019-04-30 | 2016 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,513,077 | 0 | 11,823,808 | 2,995,839 | 601,134 | 16,933,858 |
| 2019-04-30 | 2016 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,513,077 | 0 | 11,823,808 | 2,995,839 | 601,134 | 16,933,858 |
| 2019-04-30 | 2016 | Giovanni Caforio, M.D. Chairman and Chief Executive Officer | 1,513,077 | 0 | 11,823,808 | 2,995,839 | 601,134 | 16,933,858 |
| 2019-04-30 | 2018 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 1,027,212 | 0 | 4,313,576 | 2,203,913 | 349,706 | 7,894,407 |
| 2019-04-30 | 2018 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 1,027,212 | 0 | 4,313,576 | 2,203,913 | 349,706 | 7,894,407 |
| 2019-04-30 | 2018 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 1,027,212 | 0 | 4,313,576 | 2,203,913 | 349,706 | 7,894,407 |
| 2019-04-30 | 2016 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 966,115 | 0 | 4,013,210 | 1,530,654 | 351,385 | 6,971,693 |
| 2019-04-30 | 2016 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 966,115 | 0 | 4,013,210 | 1,530,654 | 351,385 | 6,971,693 |
| 2019-04-30 | 2016 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 966,115 | 0 | 4,013,210 | 1,530,654 | 351,385 | 6,971,693 |
| 2019-04-30 | 2017 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 997,294 | 0 | 4,321,014 | 1,887,005 | 303,354 | 8,816,308 |
| 2019-04-30 | 2017 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 997,294 | 0 | 4,321,014 | 1,887,005 | 303,354 | 8,816,308 |
| 2019-04-30 | 2017 | Charles Bancroft Chief Financial Officer and EVP, Head of Global Business Operations | 997,294 | 0 | 4,321,014 | 1,887,005 | 303,354 | 8,816,308 |
| 2019-04-30 | 2018 | Louis Schmukler | 804,599 | 0 | 2,047,722 | 1,065,613 | 209,439 | 4,127,373 |
| 2019-04-30 | 2018 | Louis Schmukler | 804,599 | 0 | 2,047,722 | 1,065,613 | 209,439 | 4,127,373 |
| 2019-04-30 | 2018 | Louis Schmukler | 804,599 | 0 | 2,047,722 | 1,065,613 | 209,439 | 4,127,373 |
| 2019-04-30 | 2017 | Sandra Leung EVP and General Counsel | 947,436 | 0 | 3,047,660 | 1,493,890 | 259,448 | 6,543,417 |
| 2019-04-30 | 2017 | Sandra Leung EVP and General Counsel | 947,436 | 0 | 3,047,660 | 1,493,890 | 259,448 | 6,543,417 |
| 2019-04-30 | 2017 | Sandra Leung EVP and General Counsel | 947,436 | 0 | 3,047,660 | 1,493,890 | 259,448 | 6,543,417 |
| 2019-04-30 | 2018 | Sandra Leung EVP and General Counsel | 975,860 | 0 | 3,290,794 | 1,680,159 | 296,370 | 6,243,183 |
| 2019-04-30 | 2018 | Sandra Leung EVP and General Counsel | 975,860 | 0 | 3,290,794 | 1,680,159 | 296,370 | 6,243,183 |
| 2019-04-30 | 2018 | Sandra Leung EVP and General Counsel | 975,860 | 0 | 3,290,794 | 1,680,159 | 296,370 | 6,243,183 |
| 2019-04-30 | 2017 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 796,154 | 1,400,000 | 4,425,587 | 1,576,706 | 113,522 | 8,311,969 |
| 2019-04-30 | 2017 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 796,154 | 1,400,000 | 4,425,587 | 1,576,706 | 113,522 | 8,311,969 |
| 2019-04-30 | 2018 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 1,022,500 | 0 | 4,075,218 | 1,625,039 | 311,366 | 7,034,123 |
| 2019-04-30 | 2018 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 1,022,500 | 0 | 4,075,218 | 1,625,039 | 311,366 | 7,034,123 |
| 2019-04-30 | 2018 | Thomas J. Lynch, Jr., M.D. EVP and Chief Scientific Officer | 1,022,500 | 0 | 4,075,218 | 1,625,039 | 311,366 | 7,034,123 |
| 2014-03-19 | 2012 | Charles Bancroft EVP and Chief Financial Officer | 868,635 | 0 | 2,395,753 | 1,321,979 | 318,614 | 8,567,313 |
| 2014-03-19 | 2012 | Charles Bancroft EVP and Chief Financial Officer | 868,635 | 0 | 2,395,753 | 1,321,979 | 318,614 | 8,567,313 |
| 2014-03-19 | 2012 | Charles Bancroft EVP and Chief Financial Officer | 868,635 | 0 | 2,395,753 | 1,321,979 | 318,614 | 8,567,313 |
| 2014-03-19 | 2011 | Charles Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2014-03-19 | 2011 | Charles Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2014-03-19 | 2011 | Charles Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2014-03-19 | 2013 | Francis Cuss, MB, | 736,102 | 0 | 2,016,197 | 748,372 | 153,035 | 3,719,037 |
| 2014-03-19 | 2013 | Francis Cuss, MB, | 736,102 | 0 | 2,016,197 | 748,372 | 153,035 | 3,719,037 |
| 2014-03-19 | 2013 | Francis Cuss, MB, | 736,102 | 0 | 2,016,197 | 748,372 | 153,035 | 3,719,037 |
| 2014-03-19 | 2013 | Lamberto Andreotti Chief Executive Officer | 1,686,539 | 0 | 14,586,898 | 3,799,913 | 774,396 | 20,847,746 |
| 2014-03-19 | 2013 | Lamberto Andreotti Chief Executive Officer | 1,686,539 | 0 | 14,586,898 | 3,799,913 | 774,396 | 20,847,746 |
| 2014-03-19 | 2013 | Lamberto Andreotti Chief Executive Officer | 1,686,539 | 0 | 14,586,898 | 3,799,913 | 774,396 | 20,847,746 |
| 2014-03-19 | 2012 | Lamberto Andreotti Chief Executive Officer | 1,623,077 | 0 | 9,722,004 | 3,844,864 | 818,078 | 17,201,980 |
| 2014-03-19 | 2012 | Lamberto Andreotti Chief Executive Officer | 1,623,077 | 0 | 9,722,004 | 3,844,864 | 818,078 | 17,201,980 |
| 2014-03-19 | 2012 | Lamberto Andreotti Chief Executive Officer | 1,623,077 | 0 | 9,722,004 | 3,844,864 | 818,078 | 17,201,980 |
| 2014-03-19 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2014-03-19 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2014-03-19 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2014-03-19 | 2013 | Charles Bancroft EVP and Chief Financial Officer | 901,092 | 0 | 4,778,079 | 1,128,108 | 311,230 | 7,878,016 |
| 2014-03-19 | 2013 | Charles Bancroft EVP and Chief Financial Officer | 901,092 | 0 | 4,778,079 | 1,128,108 | 311,230 | 7,878,016 |
| 2014-03-19 | 2013 | Charles Bancroft EVP and Chief Financial Officer | 901,092 | 0 | 4,778,079 | 1,128,108 | 311,230 | 7,878,016 |
| 2014-03-19 | 2013 | Sandra Leung General Counsel & Corporate Secretary | 843,087 | 0 | 2,883,914 | 844,238 | 245,048 | 4,816,287 |
| 2014-03-19 | 2013 | Sandra Leung General Counsel & Corporate Secretary | 843,087 | 0 | 2,883,914 | 844,238 | 245,048 | 4,816,287 |
| 2014-03-19 | 2013 | Sandra Leung General Counsel & Corporate Secretary | 843,087 | 0 | 2,883,914 | 844,238 | 245,048 | 4,816,287 |
| 2014-03-19 | 2012 | Sandra Leung General Counsel & Corporate Secretary | 768,738 | 0 | 2,020,399 | 907,256 | 243,163 | 5,892,772 |
| 2014-03-19 | 2012 | Sandra Leung General Counsel & Corporate Secretary | 768,738 | 0 | 2,020,399 | 907,256 | 243,163 | 5,892,772 |
| 2014-03-19 | 2012 | Sandra Leung General Counsel & Corporate Secretary | 768,738 | 0 | 2,020,399 | 907,256 | 243,163 | 5,892,772 |
| 2014-03-19 | 2011 | Sandra Leung General Counsel & Corporate Secretary | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2014-03-19 | 2011 | Sandra Leung General Counsel & Corporate Secretary | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2014-03-19 | 2011 | Sandra Leung General Counsel & Corporate Secretary | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2014-03-19 | 2013 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 564,451 | 0 | 5,890,044 | 653,134 | 340,796 | 7,448,425 |
| 2014-03-19 | 2013 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 564,451 | 0 | 5,890,044 | 653,134 | 340,796 | 7,448,425 |
| 2014-03-19 | 2013 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 564,451 | 0 | 5,890,044 | 653,134 | 340,796 | 7,448,425 |
| 2014-03-19 | 2012 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,063,209 | 0 | 3,219,625 | 1,869,807 | 450,082 | 8,343,683 |
| 2014-03-19 | 2012 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,063,209 | 0 | 3,219,625 | 1,869,807 | 450,082 | 8,343,683 |
| 2014-03-19 | 2012 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,063,209 | 0 | 3,219,625 | 1,869,807 | 450,082 | 8,343,683 |
| 2014-03-19 | 2013 | Giovanni Caforio, M.D. | 748,320 | 0 | 1,587,106 | 788,565 | 177,861 | 3,301,852 |
| 2014-03-19 | 2013 | Giovanni Caforio, M.D. | 748,320 | 0 | 1,587,106 | 788,565 | 177,861 | 3,301,852 |
| 2014-03-19 | 2013 | Giovanni Caforio, M.D. | 748,320 | 0 | 1,587,106 | 788,565 | 177,861 | 3,301,852 |
| 2014-03-19 | 2011 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2014-03-19 | 2011 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2014-03-19 | 2011 | Elliott Sigal, M.D., Ph.D. Former EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2014-03-19 | 2013 | Beatrice Cazala Former EVP, Commercial Operations | 894,694 | 0 | 3,611,980 | 895,915 | 75,609 | 5,478,198 |
| 2014-03-19 | 2013 | Beatrice Cazala Former EVP, Commercial Operations | 894,694 | 0 | 3,611,980 | 895,915 | 75,609 | 5,478,198 |
| 2014-03-19 | 2013 | Beatrice Cazala Former EVP, Commercial Operations | 894,694 | 0 | 3,611,980 | 895,915 | 75,609 | 5,478,198 |
| 2014-03-19 | 2012 | Beatrice Cazala Former EVP, Commercial Operations | 868,635 | 0 | 2,445,800 | 1,126,130 | 68,448 | 8,031,025 |
| 2014-03-19 | 2012 | Beatrice Cazala Former EVP, Commercial Operations | 868,635 | 0 | 2,445,800 | 1,126,130 | 68,448 | 8,031,025 |
| 2014-03-19 | 2012 | Beatrice Cazala Former EVP, Commercial Operations | 868,635 | 0 | 2,445,800 | 1,126,130 | 68,448 | 8,031,025 |
| 2014-03-19 | 2011 | Beatrice Cazala Former EVP, Commercial Operations | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2014-03-19 | 2011 | Beatrice Cazala Former EVP, Commercial Operations | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2014-03-19 | 2011 | Beatrice Cazala Former EVP, Commercial Operations | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2012-03-20 | 2009 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2012-03-20 | 2010 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,020,000 | 0 | 2,918,790 | 1,952,642 | 449,383 | 8,282,374 |
| 2012-03-20 | 2010 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,020,000 | 0 | 2,918,790 | 1,952,642 | 449,383 | 8,282,374 |
| 2012-03-20 | 2010 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,020,000 | 0 | 2,918,790 | 1,952,642 | 449,383 | 8,282,374 |
| 2012-03-20 | 2011 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2012-03-20 | 2011 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2012-03-20 | 2011 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,034,986 | 0 | 2,908,753 | 2,151,663 | 418,268 | 9,031,998 |
| 2012-03-20 | 2011 | Anthony C. Hooper | 711,323 | 0 | 2,307,474 | 867,206 | 273,425 | 5,889,348 |
| 2012-03-20 | 2011 | Anthony C. Hooper | 711,323 | 0 | 2,307,474 | 867,206 | 273,425 | 5,889,348 |
| 2012-03-20 | 2011 | Anthony C. Hooper | 711,323 | 0 | 2,307,474 | 867,206 | 273,425 | 5,889,348 |
| 2012-03-20 | 2010 | Sandra Leung General Counsel | 675,000 | 0 | 1,824,035 | 797,648 | 222,965 | 4,629,903 |
| 2012-03-20 | 2010 | Sandra Leung General Counsel | 675,000 | 0 | 1,824,035 | 797,648 | 222,965 | 4,629,903 |
| 2012-03-20 | 2010 | Sandra Leung General Counsel | 675,000 | 0 | 1,824,035 | 797,648 | 222,965 | 4,629,903 |
| 2012-03-20 | 2011 | Sandra Leung General Counsel | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2012-03-20 | 2011 | Sandra Leung General Counsel | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2012-03-20 | 2011 | Sandra Leung General Counsel | 724,587 | 0 | 1,827,335 | 968,140 | 213,113 | 5,491,673 |
| 2012-03-20 | 2011 | Beatrice Cazala | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2012-03-20 | 2011 | Beatrice Cazala | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2012-03-20 | 2011 | Beatrice Cazala | 895,100 | 0 | 2,602,126 | 1,353,436 | 132,567 | 5,941,167 |
| 2012-03-20 | 2009 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2012-03-20 | 2009 | Elliott Sigal, M.D., Ph.D. EVP and Chief Scientific Officer | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2012-03-20 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2012-03-20 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2012-03-20 | 2011 | Lamberto Andreotti Chief Executive Officer | 1,510,192 | 0 | 7,351,673 | 4,220,340 | 649,843 | 14,911,947 |
| 2012-03-20 | 2010 | Lamberto Andreotti Chief Executive Officer | 1,347,868 | 0 | 5,808,704 | 3,131,544 | 619,398 | 11,770,880 |
| 2012-03-20 | 2010 | Lamberto Andreotti Chief Executive Officer | 1,347,868 | 0 | 5,808,704 | 3,131,544 | 619,398 | 11,770,880 |
| 2012-03-20 | 2010 | Lamberto Andreotti Chief Executive Officer | 1,347,868 | 0 | 5,808,704 | 3,131,544 | 619,398 | 11,770,880 |
| 2012-03-20 | 2011 | Charles A. Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2012-03-20 | 2011 | Charles A. Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2012-03-20 | 2011 | Charles A. Bancroft EVP and Chief Financial Officer | 809,712 | 0 | 2,151,058 | 1,407,181 | 250,363 | 7,372,400 |
| 2012-03-20 | 2010 | Charles A. Bancroft EVP and Chief Financial Officer | 678,830 | 0 | 1,000,385 | 978,595 | 142,409 | 4,218,638 |
| 2012-03-20 | 2010 | Charles A. Bancroft EVP and Chief Financial Officer | 678,830 | 0 | 1,000,385 | 978,595 | 142,409 | 4,218,638 |
| 2012-03-20 | 2010 | Charles A. Bancroft EVP and Chief Financial Officer | 678,830 | 0 | 1,000,385 | 978,595 | 142,409 | 4,218,638 |
| 2010-03-22 | 2007 | Anthony C. Hooper President, Americas | 643,890 | 0 | 885,758 | 681,660 | 49,371 | 3,501,948 |
| 2010-03-22 | 2008 | Lamberto Andreotti President & Chief Operating Officer | 1,211,141 | 0 | 1,340,374 | 2,676,668 | 57,801 | 7,986,400 |
| 2010-03-22 | 2007 | Lamberto Andreotti President & Chief Operating Officer | 1,098,637 | 0 | 881,942 | 1,866,344 | 111,922 | 6,166,451 |
| 2010-03-22 | 2007 | Lamberto Andreotti President & Chief Operating Officer | 1,098,637 | 0 | 881,942 | 1,866,344 | 111,922 | 6,166,451 |
| 2010-03-22 | 2007 | Lamberto Andreotti President & Chief Operating Officer | 1,098,637 | 0 | 881,942 | 1,866,344 | 111,922 | 6,166,451 |
| 2010-03-22 | 2009 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2010-03-22 | 2009 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2010-03-22 | 2009 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 1,014,846 | 0 | 3,436,891 | 2,189,879 | 45,668 | 10,004,439 |
| 2010-03-22 | 2008 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 985,845 | 0 | 1,340,374 | 2,084,324 | 49,449 | 7,852,480 |
| 2010-03-22 | 2008 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 985,845 | 0 | 1,340,374 | 2,084,324 | 49,449 | 7,852,480 |
| 2010-03-22 | 2008 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 985,845 | 0 | 1,340,374 | 2,084,324 | 49,449 | 7,852,480 |
| 2010-03-22 | 2007 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 880,281 | 0 | 904,225 | 1,430,387 | 112,772 | 6,131,760 |
| 2010-03-22 | 2007 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 880,281 | 0 | 904,225 | 1,430,387 | 112,772 | 6,131,760 |
| 2010-03-22 | 2007 | Elliott Sigal, M.D., Ph.D. EVP BMS CO CSO & President R&D | 880,281 | 0 | 904,225 | 1,430,387 | 112,772 | 6,131,760 |
| 2010-03-22 | 2009 | Anthony C. Hooper President, Americas | 782,308 | 0 | 1,005,715 | 1,113,373 | 35,204 | 5,027,369 |
| 2010-03-22 | 2009 | Anthony C. Hooper President, Americas | 782,308 | 0 | 1,005,715 | 1,113,373 | 35,204 | 5,027,369 |
| 2010-03-22 | 2009 | Anthony C. Hooper President, Americas | 782,308 | 0 | 1,005,715 | 1,113,373 | 35,204 | 5,027,369 |
| 2010-03-22 | 2008 | Anthony C. Hooper President, Americas | 693,464 | 0 | 805,287 | 1,065,861 | 32,591 | 4,412,323 |
| 2010-03-22 | 2008 | Anthony C. Hooper President, Americas | 693,464 | 0 | 805,287 | 1,065,861 | 32,591 | 4,412,323 |
| 2010-03-22 | 2008 | Anthony C. Hooper President, Americas | 693,464 | 0 | 805,287 | 1,065,861 | 32,591 | 4,412,323 |
| 2010-03-22 | 2007 | Anthony C. Hooper President, Americas | 643,890 | 0 | 885,758 | 681,660 | 49,371 | 3,501,948 |
| 2010-03-22 | 2007 | Anthony C. Hooper President, Americas | 643,890 | 0 | 885,758 | 681,660 | 49,371 | 3,501,948 |
| 2010-03-22 | 2009 | James M. Cornelius Chairman & Chief Executive Officer | 1,500,000 | 0 | 5,661,943 | 4,494,825 | 136,363 | 18,221,434 |
| 2010-03-22 | 2009 | James M. Cornelius Chairman & Chief Executive Officer | 1,500,000 | 0 | 5,661,943 | 4,494,825 | 136,363 | 18,221,434 |
| 2010-03-22 | 2009 | James M. Cornelius Chairman & Chief Executive Officer | 1,500,000 | 0 | 5,661,943 | 4,494,825 | 136,363 | 18,221,434 |
| 2010-03-22 | 2008 | James M. Cornelius Chairman & Chief Executive Officer | 1,488,077 | 0 | 5,122,554 | 4,475,000 | 136,309 | 19,710,697 |
| 2010-03-22 | 2008 | James M. Cornelius Chairman & Chief Executive Officer | 1,488,077 | 0 | 5,122,554 | 4,475,000 | 136,309 | 19,710,697 |
| 2010-03-22 | 2008 | James M. Cornelius Chairman & Chief Executive Officer | 1,488,077 | 0 | 5,122,554 | 4,475,000 | 136,309 | 19,710,697 |
| 2010-03-22 | 2007 | James M. Cornelius Chairman & Chief Executive Officer | 1,352,115 | 1,062,500 | 3,148,783 | 2,220,801 | 424,954 | 12,475,667 |
| 2010-03-22 | 2007 | James M. Cornelius Chairman & Chief Executive Officer | 1,352,115 | 1,062,500 | 3,148,783 | 2,220,801 | 424,954 | 12,475,667 |
| 2010-03-22 | 2007 | James M. Cornelius Chairman & Chief Executive Officer | 1,352,115 | 1,062,500 | 3,148,783 | 2,220,801 | 424,954 | 12,475,667 |
| 2010-03-22 | 2009 | Jean-Marc Huet Former EVP & CFO | 913,361 | 0 | 1,193,867 | 0 | 42,908 | 3,750,924 |
| 2010-03-22 | 2009 | Jean-Marc Huet Former EVP & CFO | 913,361 | 0 | 1,193,867 | 0 | 42,908 | 3,750,924 |
| 2010-03-22 | 2009 | Jean-Marc Huet Former EVP & CFO | 913,361 | 0 | 1,193,867 | 0 | 42,908 | 3,750,924 |
| 2010-03-22 | 2008 | Jean-Marc Huet Former EVP & CFO | 675,000 | 100,000 | 924,598 | 1,583,993 | 285,736 | 5,133,238 |
| 2010-03-22 | 2008 | Jean-Marc Huet Former EVP & CFO | 675,000 | 100,000 | 924,598 | 1,583,993 | 285,736 | 5,133,238 |
| 2010-03-22 | 2008 | Jean-Marc Huet Former EVP & CFO | 675,000 | 100,000 | 924,598 | 1,583,993 | 285,736 | 5,133,238 |
| 2010-03-22 | 2009 | Lamberto Andreotti President & Chief Operating Officer | 1,244,730 | 0 | 1,636,206 | 3,076,402 | 56,013 | 9,005,321 |
| 2010-03-22 | 2009 | Lamberto Andreotti President & Chief Operating Officer | 1,244,730 | 0 | 1,636,206 | 3,076,402 | 56,013 | 9,005,321 |
| 2010-03-22 | 2009 | Lamberto Andreotti President & Chief Operating Officer | 1,244,730 | 0 | 1,636,206 | 3,076,402 | 56,013 | 9,005,321 |
| 2010-03-22 | 2008 | Lamberto Andreotti President & Chief Operating Officer | 1,211,141 | 0 | 1,340,374 | 2,676,668 | 57,801 | 7,986,400 |
| 2010-03-22 | 2008 | Lamberto Andreotti President & Chief Operating Officer | 1,211,141 | 0 | 1,340,374 | 2,676,668 | 57,801 | 7,986,400 |
| 2007-03-22 | 2006 | James M. Cornelius Interim Chief Executive Officer | 379,808 | 0 | 0 | 0 | 318,194 | 1,472,879 |
| 2007-03-22 | 2006 | James M. Cornelius Interim Chief Executive Officer | 379,808 | 0 | 0 | 0 | 318,194 | 1,472,879 |
| 2007-03-22 | 2006 | James M. Cornelius Interim Chief Executive Officer | 379,808 | 0 | 0 | 0 | 318,194 | 1,472,879 |
| 2007-03-22 | 2006 | Andrew R. J. Bonfield EVP & Chief Financial Officer | 809,386 | 0 | 936,138 | 740,540 | 111,543 | 3,439,770 |
| 2007-03-22 | 2006 | Andrew R. J. Bonfield EVP & Chief Financial Officer | 809,386 | 0 | 936,138 | 740,540 | 111,543 | 3,439,770 |
| 2007-03-22 | 2006 | Andrew R. J. Bonfield EVP & Chief Financial Officer | 809,386 | 0 | 936,138 | 740,540 | 111,543 | 3,439,770 |
| 2007-03-22 | 2006 | Lamberto Andreotti EVP & President WW Pharmaceuticals | 1,008,345 | 0 | 1,273,917 | 1,104,887 | 269,251 | 4,646,366 |
| 2007-03-22 | 2006 | Lamberto Andreotti EVP & President WW Pharmaceuticals | 1,008,345 | 0 | 1,273,917 | 1,104,887 | 269,251 | 4,646,366 |
| 2007-03-22 | 2006 | Lamberto Andreotti EVP & President WW Pharmaceuticals | 1,008,345 | 0 | 1,273,917 | 1,104,887 | 269,251 | 4,646,366 |
| 2007-03-22 | 2006 | Elliott Sigal, M.D., Ph.D. EVP, Chief Scientific Officer & President PRI | 728,687 | 0 | 1,078,998 | 734,616 | 68,372 | 3,746,102 |
| 2007-03-22 | 2006 | Elliott Sigal, M.D., Ph.D. EVP, Chief Scientific Officer & President PRI | 728,687 | 0 | 1,078,998 | 734,616 | 68,372 | 3,746,102 |
| 2007-03-22 | 2006 | Elliott Sigal, M.D., Ph.D. EVP, Chief Scientific Officer & President PRI | 728,687 | 0 | 1,078,998 | 734,616 | 68,372 | 3,746,102 |
| 2007-03-22 | 2006 | Stephen E. Bear SVP Human Resources | 466,101 | 0 | 512,932 | 292,524 | 38,038 | 2,148,319 |
| 2007-03-22 | 2006 | Stephen E. Bear SVP Human Resources | 466,101 | 0 | 512,932 | 292,524 | 38,038 | 2,148,319 |
| 2007-03-22 | 2006 | Stephen E. Bear SVP Human Resources | 466,101 | 0 | 512,932 | 292,524 | 38,038 | 2,148,319 |
| 2007-03-22 | 2006 | Peter R. Dolan Former Chief Executive Officer | 1,043,269 | 0 | 0 | 0 | 1,438,238 | 9,797,979 |
| 2007-03-22 | 2006 | Peter R. Dolan Former Chief Executive Officer | 1,043,269 | 0 | 0 | 0 | 1,438,238 | 9,797,979 |
| 2007-03-22 | 2006 | Peter R. Dolan Former Chief Executive Officer | 1,043,269 | 0 | 0 | 0 | 1,438,238 | 9,797,979 |
| 2007-03-22 | 2006 | Anthony C. Hooper President U.S. Pharmaceuticals | 618,000 | 0 | 569,675 | 465,045 | 44,812 | 2,424,084 |
| 2007-03-22 | 2006 | Anthony C. Hooper President U.S. Pharmaceuticals | 618,000 | 0 | 569,675 | 465,045 | 44,812 | 2,424,084 |
| 2007-03-22 | 2006 | Anthony C. Hooper President U.S. Pharmaceuticals | 618,000 | 0 | 569,675 | 465,045 | 44,812 | 2,424,084 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
